NORTH CHICAGO, Ill.,
April 30, 2019 /PRNewswire/
-- AbbVie (NYSE: ABBV), a research-based global
biopharmaceutical company, today announced experts in the
neuroscience field will present six abstracts, including data
evaluating investigational medicines from its neuroscience
pipeline, at the American Academy of Neurology (AAN) Annual
Meeting, May 4-10 in Philadelphia. The six accepted abstracts
include two oral presentations showing AbbVie's research progress
in difficult neurological conditions.
Investigators will present data on ABBV-951, a
levodopa/carbidopa prodrug, delivering a 24-hour continuous,
subcutaneous infusion under investigation for the treatment for
advanced Parkinson's disease (PD). The study evaluated the
pharmacokinetics and safety/tolerability of ABBV-951 in a
first-in-human study following the continuous subcutaneous infusion
of carbidopa and levodopa.
Investigators will also share data from a Phase 1, multiple-dose
study of elezanumab in patients with relapsing forms of multiple
sclerosis (MS). Elezanumab is an investigational fully humanized
monoclonal antibody directed against repulsive guidance molecule
A(RGMa) currently being studied in MS patients. RGMa is a potent
inhibitor of neuronal regeneration and a regulator of cell death,
and is thought to play a role in a variety of neurological
disorders.
"AbbVie's data at AAN tells the story of our continued efforts
to find ways to treat some of the most complicated and difficult
neurological conditions," said Michael
Gold, M.D., vice president, neuroscience development,
AbbVie. "We are pleased to share these important updates with
the world's leading experts at AAN, and to continue our work to
advance the research and development of these investigational
medicines."
AbbVie will also provide data evaluating the challenges in
maintaining patients with advanced PD on only oral anti-PD
medications, as well as data investigating the effectiveness of a
tool aiding doctors in identifying patients with PD who are not
adequately controlled on oral medications.
Details about AbbVie's presentations are as follows:
|
Abstract
|
Presentation
Timing
|
|
Levodopa-Carbidopa
Intestinal Gel for the Treatment of Motor Fluctuations and
Dyskinesia in Patients with Advanced Parkinson's Disease in a 'Real
World' Setting: Results of an Interim Analysis of the Multinational
Observational Long-Term Study DUOGLOBE
|
Platform
Presentation 004 on Sunday, May
5th at 1:33PM
|
|
Impact of
Carbidopa-Levodopa Enteral Suspension on Quality of Life and
Activities of Daily Living in Patients with Advanced Parkinson's
Disease: Results from a Pooled Meta-Analysis
|
Poster Session P3
on Tuesday, May 7
|
|
Medication
Adherence and Discontinuation in a National Cohort of Medicare
Beneficiaries with Advanced Parkinson's Disease
|
Poster Session P3
on Tuesday, May 7
|
|
A Novel
Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous
Subcutaneous Infusion Treatment for Parkinson's
Disease
|
Poster Session P3
on Tuesday, May 7
|
|
MANAGE-PD: A
Clinician-Reported Tool to Identify Patients with Parkinson's
Disease Inadequately Controlled on Oral Medications – Results from
Vignette-Based Validation
|
Poster Session P5
on Thursday, May 9
|
|
A Phase 1,
Multiple-Dose Study of Elezanumab (ABT-555) in Patients with
Relapsing Forms of Multiple Sclerosis
|
Platform
Presentation 001 on Friday, May
10th at 1:00PM
|
About Elezanumab
Elezanumab is an investigational
fully humanized monoclonal antibody directed against repulsive
guidance molecule A (RGMa) currently being studied in multiple
sclerosis patients.
About ABBV-951
ABBV-951 is an investigational
levodopa/carbidopa prodrug delivered subcutaneously being studied
for the treatment of advanced Parkinson's disease.
About AbbVie
AbbVie is a global, research and
development-based biopharmaceutical company committed to developing
innovative advanced therapies for some of the world's most complex
and critical conditions. The company's mission is to use its
expertise, dedicated people and unique approach to innovation to
markedly improve treatments across four primary therapeutic areas:
immunology, oncology, virology and neuroscience. In more than
75 countries, AbbVie employees are working every day to advance
health solutions for people around the world. For more information
about AbbVie, please visit us at www.abbvie.com.
Follow @abbvie on Twitter, Facebook, LinkedIn or
Instagram.
Forward-Looking Statements
Some statements in this
news release are, or may be considered, forward-looking statements
for purposes of the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "anticipate," "project" and
similar expressions, among others, generally identify
forward-looking statements. AbbVie cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, challenges to
intellectual property, competition from other products,
difficulties inherent in the research and development process,
adverse litigation or government action, and changes to laws and
regulations applicable to our industry. Additional information
about the economic, competitive, governmental, technological and
other factors that may affect AbbVie's operations is set forth in
Item 1A, "Risk Factors," of AbbVie's 2018 Annual Report on Form
10-K, which has been filed with the Securities and Exchange
Commission. AbbVie undertakes no obligation to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
View original
content:http://www.prnewswire.com/news-releases/abbvie-to-present-new-and-updated-data-of-investigational-medicines-for-parkinsons-disease-and-multiple-sclerosis-at-2019-american-academy-of-neurology-annual-meeting-300840219.html
SOURCE AbbVie